Companies with combination drug products containing hydrocortisone acetate and pramoxine hydrochloride have until Oct. 31 to file data and information in support of hearing requests concerning the withdrawal of such products from the market. FDA granted an extension to the original Aug. 31 filing date, set in a July 1 Federal Register notice, after Parke-Davis, Ferndale Labs, Copley Pharmaceutical, and Reed and Carnrick appealed for an end of November filing date.
You may also be interested in...
The US firm gets development and co-commercial rights to MORAb-202 for $650m up front. BMS joins AstraZeneca, Merck & Co. and Gilead in recent ADC deal-making.
The recently concluded BIO annual meeting included several sessions focused on the practice of business development. In this extra edition of our BIO 2021 notebook, Scrip collected observations about best practices for partnerships.
The company’s rollout plans for Ayvakit appear similar to its approach when it marketed the drug for GIST, with an education plan to help boost sales.